Physician profile
Eric C Lisic
NPI 1356632152
$5,720.46
in general payments reported to CMS, 2019-2025
28 companies · $1,411 in 2025
The $1,411 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,387 · 2020: $336 · 2021: $68.18 · 2023: $459 · 2024: $1,059 · 2025: $1,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,928.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,048.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $606.77 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $605.01 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $538.49 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $367.60 | 2019 | |
| Pfizer INC. | $344.40 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $331.41 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.14 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $249.61 | 2019-2024 | Veozah |
| Sunovion Pharmaceuticals INC. | $178.51 | 2019 | |
| Sanofi-Aventis U.S. LLC | $168.48 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.89 | 2019-2024 | Xifaxan, Trulance |
| Amgen INC. | $136.37 | 2019-2020 | |
| Exact Sciences Corporation | $109.33 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $105.05 | 2019-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $86.40 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $75.79 | 2023-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $67.36 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $53.39 | 2024-2025 | |
| Shield Therapeutics INC | $41.48 | 2024 | |
| Axsome Therapeutics, INC. | $41.34 | 2025 | Symbravo, Auvelity |
| Dexcom, INC. | $30.45 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $28.42 | 2023-2025 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $28.16 | 2025 | Zoryve |
| Shire North American Group INC | $25.85 | 2019 | |
| Corcept Therapeutics | $22.06 | 2025 | Korlym |
| Medtronic, INC. | $20.16 | 2024 | Minimed 780g |
| Mylan Specialty L.P. | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lisic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.